European Journal of Dermatology

, Volume 28, Issue 3, pp 429–431 | Cite as

Dermpath & Clinic: Juvenile xanthogranuloma

  • Verena G. FringsEmail author
  • Matthias Goebeler
  • Marion Wobser
Residents’corner, May-June 2018


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dehner LP. Juvenile xanthogranuloma in the first decades of life. A clinicopathologic study of 174 cases with cutaneous an extracutaneous manifestations. Am J Surg Pathol 2003; 5: 579–93.Google Scholar
  2. 2.
    Janssen D, Harms D. Juvenile xanthogranuloma in childhood and adolescence:a clinicopathological study of 129 patients from the Kiel pediatric tumor registry. Am J Surg Pathol 2005; 29: 21–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Jung T, Emmert S, Günzl HJ, Neumann C, Rünger TM. Congenital manifestations of juvenile xanthogranuloma (large nodular form). Hautarzt 2000; 51: 423–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Chang MW. Update on juvenile xanthogranuloma:unusual cutaneous and systemic variants. Semin Cutan Med Surg 1999; 18: 195–205.CrossRefPubMedGoogle Scholar
  5. 5.
    Cypel TKS, Zuker RM. Juvenile xanthogranuloma:case report and review of the literature. Can J Plast Surg 2008; 16: 175–7.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hernandez–Martin A, Baselga E, Drolet BA, Esterly NB. Juvenile xanthogranuloma. J Am Acad Dermatol 1997; 36: 335–67.CrossRefGoogle Scholar
  7. 7.
    Weitzman S, Jaffe R. Uncommon histiocytic disorders:the nonlangerhans cell histiocytoses. Pediatr Blood Cancer 2005; 45: 256–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Samuelov L, Kinori M, Chamlin SL, et al. Risk of intraocular and other extracutaneous involvement in patients with cutaneous juvenile xanthogranuloma. 2018. Ahead of print.Google Scholar
  9. 9.
    Paxton CN, O’Malley DP, Bellizzi AM, et al. Genetic evaluation of juvenile xanthogranuloma:genomic abnormalities are uncommon in solitary lesions, advanced cases may show more complexity. Mod Pathol 2017; 30: 1234–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 2014; 124: 3007–15.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Sangüeza OP, Salmon JK, White CR Jr., Beckstead JH. Juvenile xanthogranuloma:a clinical, histopathologic and immunohistochemical study. J Cutan Pathol 1995; 22: 327–35.CrossRefPubMedGoogle Scholar
  12. 12.
    Sonoda T, Hashimoto H, Enjoji M. Juvenile xanthogranuloma. Clinicopathologic analysis and immunohistochemical study of 57 patients. Cancer 1985; 56: 2280–6.PubMedGoogle Scholar
  13. 13.
    Zelger B, Cerio R, Orchard G, Wilson–Jones E. Juvenile and adult xanthogranuloma. A histological and immunohistochemical comparison. Am J Surg Pathol 1994; 18: 126–35. A B C Figure 1. A) Medial aspect of the feet of the patient, showing greenish macules and papules. B) Dermoscopic examination showing green and yellow dots and clods, some of which consist of dark central parts, surrounded by pale edges. C) Histopathological examination revealing pinkish mucinous material under the stratum corneum (haematoxylin and eosin staining;×100 magnification).CrossRefPubMedGoogle Scholar
  14. 14.
    Haroche J, Abla O. Uncommon histiocytic disorders:Rosai–Dorfman, juvenile xanthogranuloma, and Erdheim–Chester disease. Hematology Am Soc Hematol Educ Program 2015; 2015: 571–8.PubMedCrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2018

Authors and Affiliations

  • Verena G. Frings
    • 1
    Email author
  • Matthias Goebeler
    • 1
  • Marion Wobser
    • 1
  1. 1.Department of Dermatology, Venereology and AllergologyUniversity Hospital WürzburgWürzburgGermany

Personalised recommendations